Evolving pregnancy screening options, such as noninvasive prenatal testing (NIPT), offer early genetic screening for chromosomal conditions using just one tube of blood—as early as 10 weeks into a pregnancy. Noninvasive testing provides high detection rates, low false-positive results, and no risk to mother and baby.
Other prenatal screening and diagnostic tests may require more than one office visit, multiple blood draws, or carry a higher risk of false-positive results.1-4 Diagnostic tests, such as chorionic villus sampling (CVS) or amniocentesis, provide definite results for most chromosome conditions but have an associated risk of miscarriage.
NIPT analyzes cell-free DNA from a maternal blood sample (mixture of fetal and maternal DNA) to screen for common chromosomal conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).
The American Congress of Obstetricians and Gynecologists (ACOG) and International Society of Prenatal Diagnosis (ISPD), along with other professional societies, have stated that NIPT is an available screening option for all pregnant women.5,6